New hope for Hard-to-Treat myeloma: experimental drug enters human trials
NCT ID NCT06433947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called OPN-6602, alone or with a steroid, in 130 people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. It's too early to know if it will work, but researchers hope it may offer a new option for patients who have run out of standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OPN-6602 (a targeted drug) and dexamethasone (a steroid)
What this could lead to
If successful, this could lead to a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial with only 130 participants, focused mainly on safety. The drug may not work well or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson
RECRUITINGGilbert, Arizona, 85234, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory Winchip Cancer Center
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Center Institute University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Cancer Institute
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093-0698, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Clinical Research Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of North Carolina Hospitals at Hillsborough
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••